Overview

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain
Phase:
Phase 2
Details
Lead Sponsor:
KAI Pharmaceuticals
Collaborator:
Trident Clinical Research Pty Ltd
Treatments:
Lidocaine